Imago BioSciences   Report issue

For profit Phase 1 Phase 2
Founded: San Carlos CA United States (2012)
Status: Acquired by Merck (2022)

Organization Overview

First Clinical Trial
2016
NCT02842827
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Imago BioSciences | Imago BioSciences,Inc.

Active Ingredients

Drugs in Phase 2 Trials (2)

atezolizumab (Tecentriq) (1 trial)

img-7289 (10 trials)

Drugs in Phase 1 Trials (2)

tretinoin (Retin-A) (1 trial)

venetoclax (venclexta) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Myelodysplastic Syndromes (Phase 1)

Polycythemia (Phase 2)

Polycythemia Vera (Phase 2)

Primary Myelofibrosis (Phase 1)

Thrombocythemia, Essential (Phase 2)

Thrombocytosis (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 10
  • # of Trial APIs: 4